title: The authors' reply to Allen et al.: "A Comment on Boyers et al.: 'eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal'".
authors: Dwayne
authors: D
authors: Boyers
authors: Xueli
authors: X
authors: Jia
authors: David
authors: D
authors: Jenkinson
authors: Graham
authors: G
authors: Mowatt
mesh_terms: D001565:Benzoates / Q000627:therapeutic use*; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D013673:Technology Assessment, Biomedical / Q000379:methods*
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles